AbstractThe RV144 efficacy trial conducted in Thailand provided the first evidence that an HIV vaccine could provide a modest level of protection against HIV acquisition (31.2% at 42 months of follow-up) in populations at low risk for HIV infection. Vaccine efficacy appeared to be higher (60%) at 12 months post vaccination, suggesting an early, but nondurable, vaccine effect. This breakthrough finding led to identification of immune correlates of risk, antibodies directed against the V2 loop, paving the way to new vaccine designs and clinical trials to better characterization of the vaccine-induced adaptive and innate humoral and cell-mediated immune responses in peripheral and mucosal compartments. Whether the RV144 correlates of risk are ...
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the...
The immune correlates of risk analysis and recent non-human primate (NHP) challenge studies have gen...
The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine eff...
AbstractThe RV144 efficacy trial conducted in Thailand provided the first evidence that an HIV vacci...
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition. The pr...
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major ...
BACKGROUND: The RV144 trial on the ALVAC/AIDSVAX candidate HIV vaccine, carried out in Thailand, sho...
Abstract A press conference on Thursday September 24 in Bangkok, Thailand, released data that an exp...
A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk ...
A press conference on Thursday September 24 in Bangkok, Thailand, released data that an experimental...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
Background. A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Ga...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However...
recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully ...
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the...
The immune correlates of risk analysis and recent non-human primate (NHP) challenge studies have gen...
The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine eff...
AbstractThe RV144 efficacy trial conducted in Thailand provided the first evidence that an HIV vacci...
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition. The pr...
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major ...
BACKGROUND: The RV144 trial on the ALVAC/AIDSVAX candidate HIV vaccine, carried out in Thailand, sho...
Abstract A press conference on Thursday September 24 in Bangkok, Thailand, released data that an exp...
A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk ...
A press conference on Thursday September 24 in Bangkok, Thailand, released data that an experimental...
The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV vaccine fiel...
Background. A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Ga...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However...
recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully ...
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the...
The immune correlates of risk analysis and recent non-human primate (NHP) challenge studies have gen...
The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine eff...